Abstract
OPLS discriminant analysis (OPLS-DA) was successfully applied for the selection of a limited number of gene transcripts necessary to discriminate PTPN11 and RAS mutated cells in acute lymphoblastic leukaemia (ALL) patients. The original set of 273 variables with VIP (1) values higher than 2.0 in the OPLS-DA model could be further reduced to 200 by elimination of less informative variables in the PCA class models adopted for SIMCA classification. The above 200 transcripts not only achieve a satisfactory discrimination accuracy between PTPN11 and RAS mutated cells but also indicate clearly that wild type samples belong to none of the mutated class models. In this list it was possible to identify candidate genes that could be involved in the molecular mechanisms discriminating PTPN11 and RAS mutations in ALL. Among them CBFA2T2, a member of the “ETO” family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
Keywords: ALL, OPLS, leukaemia, gene transcripts, mutations, SIMCA classification, Partial Least Squares, PLS, PLS-DA, SIMCA, PDQuest, OPLS-DA, acute lymphoblastic leukaemia, PTPN11, RAS, PCA, DModX, DCrit, 17AAG, EPH136, CBFA2T2, MTGR1, CBFA2T1, MTG8, ETO, N-CoR, SMRT, mSin3A, a, HDAC, RUNX1-CBFA2T1
Combinatorial Chemistry & High Throughput Screening
Title: OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Volume: 14 Issue: 1
Author(s): Giuseppe Musumarra, Daniele F. Condorelli and Cosimo G. Fortuna
Affiliation:
Keywords: ALL, OPLS, leukaemia, gene transcripts, mutations, SIMCA classification, Partial Least Squares, PLS, PLS-DA, SIMCA, PDQuest, OPLS-DA, acute lymphoblastic leukaemia, PTPN11, RAS, PCA, DModX, DCrit, 17AAG, EPH136, CBFA2T2, MTGR1, CBFA2T1, MTG8, ETO, N-CoR, SMRT, mSin3A, a, HDAC, RUNX1-CBFA2T1
Abstract: OPLS discriminant analysis (OPLS-DA) was successfully applied for the selection of a limited number of gene transcripts necessary to discriminate PTPN11 and RAS mutated cells in acute lymphoblastic leukaemia (ALL) patients. The original set of 273 variables with VIP (1) values higher than 2.0 in the OPLS-DA model could be further reduced to 200 by elimination of less informative variables in the PCA class models adopted for SIMCA classification. The above 200 transcripts not only achieve a satisfactory discrimination accuracy between PTPN11 and RAS mutated cells but also indicate clearly that wild type samples belong to none of the mutated class models. In this list it was possible to identify candidate genes that could be involved in the molecular mechanisms discriminating PTPN11 and RAS mutations in ALL. Among them CBFA2T2, a member of the “ETO” family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
Export Options
About this article
Cite this article as:
Musumarra Giuseppe, F. Condorelli Daniele and G. Fortuna Cosimo, OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia, Combinatorial Chemistry & High Throughput Screening 2011; 14 (1) . https://dx.doi.org/10.2174/1386207311107010036
DOI https://dx.doi.org/10.2174/1386207311107010036 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Chelating Agents for Metal Intoxication
Current Medicinal Chemistry The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N
Mini-Reviews in Organic Chemistry Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Finding Drug Targets Through Analysis of the Platelet Transcriptome
Current Pharmaceutical Design Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design The Role of Quercetin, Flavonols and Flavones in Modulating Inflammatory Cell Function
Inflammation & Allergy - Drug Targets (Discontinued) Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry